Lanadelumab Reduces Pediatric HAE Attacks 95% in Real-World Analysis
Real-world data presented at the ACAAI 2026 meeting showed lanadelumab (Takhzyro) reduced HAE attacks by 95% in pediatric patients, according to a retrospective chart review. The FDA expanded its approval to children aged 2+ in 2023. Phase 3 SPRING study results also showed a 94.8% attack rate reduction. Takeda is the drug's manufacturer.



